Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Structure Therapeutics Inc. (NASDAQ: GPCR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Structure Therapeutics is incorporated in the Cayman Islands and its American Depositary Shares, each representing three ordinary shares, are registered and listed on the Nasdaq Global Market under the symbol GPCR. The company files reports and current updates with the U.S. Securities and Exchange Commission in connection with its operations and capital markets activities.
Investors reviewing GPCR SEC filings will find current reports on Form 8-K that cover topics such as quarterly financial results, corporate updates, and outcomes of the annual general meeting of shareholders. For example, the company has furnished press releases announcing second and third quarter financial results and business updates via Form 8-K, and has reported shareholder voting results on director elections, auditor ratification, and advisory votes on executive compensation and say-on-frequency matters.
Structure Therapeutics also utilizes an automatic shelf registration statement on Form S-3 to conduct public offerings of American Depositary Shares and pre-funded warrants. Related prospectus supplements and offering documents are filed with the SEC and referenced in the company’s press releases. These filings provide details on the terms of upsized underwritten public offerings, gross proceeds, and the involvement of joint book-running managers and co-managers.
Through this filings page, users can monitor how Structure Therapeutics reports its financial condition, shareholder actions, and significant corporate events in its SEC submissions. Stock Titan enhances access to these documents with tools to quickly locate relevant 8-Ks and registration-related materials and to follow the company’s ongoing reporting history as a Nasdaq-listed clinical-stage biopharmaceutical company focused on oral small molecule GPCR-targeted therapies.
Structure Therapeutics Inc. (GPCR) – Form 4 insider filing
Director Eric Dobmeier reported the grant of 51,804 share options on 23 June 2025. The options carry an exercise price of $7.37 per ordinary share, equal to the fair-market value on the grant date. Vesting occurs in equal monthly instalments over twelve months beginning 23 June 2025; any unvested portion will become fully vested immediately prior to the company’s 2026 annual shareholder meeting. The options expire on 22 June 2035.
Following this grant, Mr. Dobmeier beneficially owns 51,804 derivative securities and no changes to his non-derivative share holdings were disclosed. Ownership is reported as direct. Each American Depositary Share represents three ordinary shares, but the filing reports the transaction in ordinary-share terms.
No open-market purchases, sales, or other equity transactions were reported. The filing therefore represents a routine board compensation event rather than a market transaction and is unlikely to have a material impact on near-term share price.
Structure Therapeutics (GPCR) reported a Form 4 filing disclosing insider trading activity by Director Sharon Tetlow on June 23, 2025. The transaction involved the acquisition of derivative securities in the form of stock options.
Key transaction details:
- Acquired 51,804 stock options to purchase ordinary shares
- Exercise price set at $7.37 per share, based on ADS trading price
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting accelerates to immediately prior to 2026 annual shareholder meeting
Each American Depositary Share (ADS) represents three ordinary shares of the company. The options were granted at fair market value based on the ADS trading price at the time of grant.
Structure Therapeutics (GPCR) Director Daniel G. Welch received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 51,804 share options to purchase ordinary shares at an exercise price of $7.37 per share.
Key details of the option grant:
- Exercise price is based on the fair market value of ordinary shares on grant date
- Options vest monthly over 12 months from June 23, 2025
- Full vesting accelerates before the 2026 annual shareholder meeting
- Options expire on June 22, 2035
- Each ADS (American Depositary Share) represents 3 ordinary shares
This equity compensation grant aligns with standard director compensation practices and demonstrates continued commitment to the company's long-term growth.